Survival Benefit of Palbociclib/Fulvestrant in HR+/HER2- Breast Cancer

In recent years and across multiple lines of therapy, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with hormonal therapy has become a standard of care for patients with advanced, hormone-receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer. As previously reported, in the PALOMA-3 trial (N = 521) the combination of the CDK4/6 […]

Read More

Atezolizumab/Nab-Paclitaxel Combo New Standard of Care for PD-L1+ TNBC

The 2018 European Society for Medical Oncology (ESMO) Congress was held from October 19 to 23 in Munich, Germany. Nearly 28,000 participants, including oncology professionals, patient advocates, and industry representatives, attended from around the world to hear the most recent updates in oncology, focusing on innovation, integration, and sustainability of cancer care. Over the next […]

Read More

liquid-biopsy-nsclc-primelines

Utility of Liquid Biopsy for Mutation Detection in NSCLC

In non-small lung cancer (NSCLC), genetic alterations in genes such as EGFR, ALK, ROS1, and BRAF have been validated as reliable targets, and molecular testing and genotype-driven targeted therapy is the standard of care for patients with advanced NSCLC harboring these alterations. However, tumor tissue may be difficult to obtain or yield inadequate samples to […]

Read More

Lurbinectedin Active in BRCA1/2-Mutated Advanced Breast Cancer

Patients with advanced breast cancer who carry germline mutations in BRCA1/2 genes are highly sensitive to DNA damage due to deficiencies in homologous recombination repair (HRR) mechanisms. Lurbinectedin, an analog of the DNA damaging agent trabectedin, is a selective inhibitor of the transcription of protein-coding genes that results in accumulation of double-strand DNA breaks. In […]

Read More

FDA Approves Four New Oncology/Hematology Indications in September

New PD-1 Inhibitor for Cutaneous Squamous Cell Carcinoma. The United States Food and Drug Administration (FDA) approved a novel PD-1 inhibitor, cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals), for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radiation. Approval was based on results from […]

Read More

CT Screening Reduces Lung Cancer Mortality in High-Risk Men and Women

The uptake of lung cancer screening is low, despite the fact that the National Lung Screening Trial (NLST) found a 20% relative reduction in lung cancer mortality for high-risk individuals (current and former heavy smokers) with annual screening using low-dose computed tomography (CT). Interestingly, a post-hoc analysis of this trial suggested a differential benefit of […]

Read More

First-Line Atezolizumab Plus Chemotherapy Prolongs Survival in SCLC

For more than 20 years, the standard of care for newly diagnosed patients with extensive stage small cell lung cancer (SCLC) has been the combination of platinum (cisplatin or carboplatin) and etoposide chemotherapy. Although this combination yields high response rates (60% to 65%), outcomes remain poor, with a median survival of around 10 months. In […]

Read More

First-Line Brigatinib Superior to Crizotinib in ALK-Positive NSCLC

Patients with metastatic non-small cell lung cancer (NSCLC) with molecular alterations in the ALK gene are sensitive to treatment with ALK-targeted tyrosine kinase inhibitors (TKIs). For many years, the ALK inhibitor crizotinib was the standard of care in this setting, though it has recently been replaced by the second-generation ALK inhibitor alectinib, on the basis […]

Read More

Durvalumab Prolongs Overall Survival in Unresectable Stage III NSCLC

The 19th World Conference on Lung Cancer (WCLC) was recently held from September 23 to 26 in Toronto, Ontario, Canada. Important results were presented from several studies that have the potential to impact clinical practice. Over the next few weeks, prIME LINES will highlight some key results, beginning with highly anticipated overall survival (OS) data […]

Read More